Polymorphism chức năng trong gen EpCAM liên quan đến sự xuất hiện và tình trạng bệnh tiến triển của ung thư cổ tử cung ở quần thể người Trung Quốc

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19 Chen X, Li H, Qiao Y, Yu D, Guo H et al (2011) Association of CD28 gene polymorphism with cervical cancer risk in a Chinese population. Int J Immunogenet 38:51–54 Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044 Louie KS, de Sanjose S, Diaz M, Castellsague X, Herrero R et al (2009) Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 100:1191–1197 Chong JM, Speicher DW (2001) Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM). J Biol Chem 276:5804–5813 Went PT, Lugli A, Meier S, Bundi M, Mirlacher M et al (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35:122–128 Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell–cell adhesion molecule. J Cell Biol 125:437–446 Munz M, Kieu C, Mack B, Schmitt B, Zeidler R et al (2004) The carcinoma-associated antigen EpCAM upregulates The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation and induces cell proliferation. Oncogene 23:5748–5758 Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M et al (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818–5824 Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T, Hirata K et al (2007) Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 43:869–877 Trzpis M, McLaughlin PM, van Goor H, Brinker MG, van Dam GM et al (2008) Expression of EpCAM is up-regulated during regeneration of renal epithelia. J Pathol 216:201–208 Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, van Krieken H et al (1996) Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148:865–875 Aubele M, Werner M (1999) Heterogeneity in breast cancer and the problem of relevance of findings. Anal Cell Pathol 19:53–58 Golub TR (2001) Genome-wide views of cancer. N Engl J Med 344:601–602 Jiang L, Zhang C, Li Y, Yu X, Zheng J et al (2011) A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population. Breast Cancer Res Treat 126:487–495 Jiang L, Liang J, Jiang M, Yu X, Zheng J et al (2011) Functional polymorphisms in the NBS1 gene and acute lymphoblastic leukemia susceptibility in a Chinese population. Eur J Haematol 86:199–205 Lu J, Yang L, Zhao H, Liu B, Li Y, et al. (2011) The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in southern and eastern chinese populations. Hum Mutat 32(11): 1299–308 Liu B, Chen D, Yang L, Li Y, Ling X et al (2010) A functional variant (–1304T > G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity. Carcinogenesis 31:1405–1411 Basak S, Speicher D, Eck S, Wunner W, Maul G et al (1998) Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst 90:691–697 Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D et al (2007) A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 5:553–567 Winter MJ, Nagelkerken B, Mertens AE, Rees-Bakker HA, Briaire-de Bruijn IH et al (2003) Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res 285:50–58 Maetzel D, Denzel S, Mack B, Canis M, Went P et al (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11:162–171 Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627–5629 Gutzmer R, Li W, Sutterwala S, Lemos MP, Elizalde JI et al (2004) A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells. J Immunol 173:1023–1032 Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111 Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988 Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW et al (2008) CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 8:784–804 van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM et al (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31:1913–1921 Brunner A, Prelog M, Verdorfer I, Tzankov A, Mikuz G et al (2008) EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol 61:307–310 Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C et al (2008) Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 14:5849–5855 Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL et al (1999) Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 162:1462–1466 Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC et al (2000) The expression of Ep-CAM (17–1A) in squamous cell cancers of the lung. Hum Pathol 31:482–487 Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C et al (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10:3131–3136 Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S et al (2004) Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10:2659–2669 Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP et al (2009) Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 15:1162–1169 Ensinger C, Kremser R, Prommegger R, Spizzo G, Schmid KW (2006) EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases. J Immunother 29:569–573 Ralhan R, Cao J, Lim T, Macmillan C, Freeman JL et al (2010) EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 10:331 Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96:417–423 Armstrong A, Eck SL (2003) EpCAM: A new therapeutic target for an old cancer antigen. Cancer Biol Ther 2:320–326 Balzar M, Winter MJ, de Boer CJ, Litvinov SV (1999) The biology of the 17–1A antigen (Ep-CAM). J Mol Med 77:699–712 Braun S, Pantel K (1998) Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat 52:201–216 Momburg F, Moldenhauer G, Hammerling GJ, Moller P (1987) Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 47:2883–2891 Bergsagel PL, Victor-Kobrin C, Brents LA, Mushinski JF, Kuehl WM (1992) Genes expressed selectively in plasmacytomas: markers of differentiation and transformation. Curr Top Microbiol Immunol 182:223–228